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Received June 21, 1990; accepted December 6, 1990. stimulus for ANP release from atrial cardiomyocytes (12). The sympathetic nervous system also plays a role in the regulation of ANP secretion and in mediating the effects of ANP on target cells (13). The physiological signal given by release of ANP into the blood is transmitted intracellularly by cyclic guanosine monophosphate (cGMP) (14) (15) (16) . Interestingly, release of cGMP from cultured cells into the medium has been observed after stimulation with the hormone (17) . Also, high concentrations of ANP in plasma in vivo cause an increase in cGMP concentrations in plasma (18, 19) . In patients with heart diseases, good correlations have been found between cGMP and increased ANP concentrations and with clinically assessed severity of congestive heart failure (5).
Several reports about ANP concentrations in plasma from patients with impaired cardiovascular function have been published (1) (2) (3) (4) (5) (6) (7) (8) (9) showing an ANP-specific extrusion of cGMP from isolated aorta into the medium, whereas nitroprusside had no effect on the release of cGMP.
Encouraged by these results, we evaluated the specificity, sensitivity, and clinical efficiency of cGMP as a marker of diseases associated with increased concentrations of ANP in plasma, particularly congestive heart failure.
Materials and Methods

Stabilityof cGMP
Blood was drawn from the cubital vein of healthy volunteers into tubes coated with EDTA (1.5 mg/mL of blood), sodium citrate (0.106 mmollmL), or lithium heparin (15 units/mL), or without any additives, and centrifuged without delay. The plasma was divided into two portions and stored at room temperature or at 4#{176}C. After various intervals (2-10 mm for determination of half-life, 5-24 h for determination of stability), 250-tL aliquots were frozen at -20 #{176}C.
Patients and Healthy Volunteers
To establish reference values for cGMP, we took rheumatologic diseases (n = 13; 52 ± 16 years), psychiatric diseases (n = 22; 46 ± 13 years), neurologic diseases (n = 36; 44 ± 17 years), and hematologic neoplasias (n = 39; 56 ± 13 years). Patients taking antihypertensive drugs were excluded from this study, as were those whose blood pressures exceeded 180/100 mmHg at the time of blood sample collection. Twelve further patients (three women, nine men; ages 26-61, mean ± SD = 41 ± 14 years) with renal failure (n = 9; 41 ± 14 years) or glomerulonephritis (n = 3; 40 ± 19 years) formed the group of patients with renal diseases. All of these subjects had increased concentrations of creatinine in plasma (range 186-652 molIL, mean ± SD = 319 ± 160). Five additional patients with both cardiac and renal failure were excluded.
Diagnostic sensitivity was determined in a group of 69 patients (16 women, 53 men; ages 20-76, mean ± SD = 57 ± 10 years) from the Intensive Care Unit of the Department of Internal Medicine, University Hospital of Innsbruck, Austria, and from the Rehabilitation Center in Grossgmain, Salzburg, Austria, who had manifest congestive heart failure [New York Heart Association (NYHA) stages II-IV] at the time of blood sampling. This group comprised 37 patients with congestive heart failure after myocardial infarction (mean age ± SD =59 ± 9 years), 15 with coronary heart diseases (57 ± 7 years), eight with valvular diseases (53 ± 15 years), seven with cardiomyopathy (48 ± 9 years), one with a sinuatrial block (56 years) and one with congestive heart failure of unknown origin (60 years). The criteria for exclusion were the same as mentioned above (hypertension, antihypertensive drug therapy, and plasma creatinine concentrations exceeding 125 mol/L).
All blood samples were collected into EDTA-coated tubes (1.5 g/L of blood). After centrifugation for 10 miii at room temperature, plasma was stored at -20 #{176}C until assayed.
Effect of ANP and GTN on cGMP in Plasma
Two healthy volunteers (one 24-year-old man, 80 kg; one 22-year-old woman, 52 kg) each underwent two experiments.
In all four experiments, blood pressure and heart rate were monitored at 1-mm intervals. 
GTN infusion:
After the same resting period, an infusion of 50 mL of isotonic saline containing 10 mg of GTN was started, at a rate of 1 mL/mun (0.2 mg/mm). After each 10-mm period, the infusion rate was doubled. Total doses of GTN were 10 mg for the man and 6 mg (infusion stopped due to onset of headache) for the woman. Blood was withdrawn from the ipsilateral cubital vein after rinsing the canula with isotonic saline; 2 mL of blood was drawn and discarded after each rinsing step. The ANP bolus and the GTN infusion were separated by at least one week. 
Analyses
For plasma extraction, 1 mL of ethanol was added to 250 L of plasma. After Figure 2 shows the histograms for cGMP concentrations in plasma from healthy blood donors (a), patients without cardiovascular or renal impairment (b), and patients with congestive heart failure (c). neither of these groups showed any effect of sex or age on plasma cGMP. The distribution of cGMP concentrations in the different noncardiac disease groups is shown in Figure 3 . All 12 patients with chronic renal failure or glomerulonephritis had increased cGMP concentrations in plasma (Figure 3) Figure 4 demonstrates that an upper cutoff value of 6.6 nmol/L calculated by the Youden index for patients without cardiovascular or renal impairment has the greatest efficiency (0.940). For the 95th percentile concentration (6.8 nmol/ L), efficiency was lower (0.929). Therefore, we chose the cutoff value of 6.6 nmol/L for our calculations, for which the sensitivity was 94.2% and the specificity was 93.7% for manifest congestive heart failure.
Effect of ANP and GTN on cGMP in plasma: Concentrations of cGMP in plasma before and during infusion of GTN and a bolus of ANP are shown in Figure 5 . GTN had no significant effect on plasma cGMP, whereas a bolus of ANP markedly increased plasma cGMP concentrations within 2 mm.
Discussion
The rapid increase in cGMP in plasma after a bolus of ANP, the high diagnostic sensitivity of cGMP for manifest congestive heart failure, and the increased cGMP concentrations in patients with chronic renal diseases imply that increases in plasma cGMP reflect increases in plasma ANP concentrations. Additionally, the results There is no evidence that the reaction of plasma cGMP to ANP is different in patients with cardiac impairment (30).
Thus far, the exact molecular mechanism of cGMP secretion into plasma after stimulation with ANP is not known. Obviously, it represents a specific reaction stimulated by ANP and provides another mechanism for regulation of intracellular cGMP in addition to cleavage of the nucleotide by phosphodiesterases.
The correlation between ANP and cGMP found by Hirata et However, measurements of plasma cGMP could provide a useful tool for monitoring therapeutic effectiveness in congestive heart failure (37) . In addition, cGMP could support the diagnosis of mild forms of the disease (NYHA stages I and II): physical exercise under standardized conditions causes an increase in ANP concentrations to pathological values in patients with mild congestive heart failure, whereas in healthy persons ANP concentrations do not exceed the normal range (38, 39). In a preliminary study, we obtained analogous results for cGMP concentrations in plasma.
Finally, we conclude that measurement of plasma cGMP is suitable for routine diagnostic applications, whereas pre-analytical and analytical difficulties can obscure the interpretation of routine determinations of
